Tag Archives: Alan Carr

Needham Sticks to Its Buy Rating for Intercept Pharma (ICPT)

Needham analyst Alan Carr maintained a Buy rating on Intercept Pharma (ICPT – Research Report) today and set a price target of $150.00. The company’s shares closed last Monday at $75.23. According to TipRanks.com, Carr is a 1-star analyst with

Needham Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

In a report released today, Alan Carr from Needham maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $135.00. The company’s shares closed last Monday at $86.03. According to TipRanks.com, Carr is a

Needham Remains a Buy on Cara Therapeutics (CARA)

In a report released today, Alan Carr from Needham maintained a Buy rating on Cara Therapeutics (CARA – Research Report), with a price target of $35.00. The company’s shares closed last Monday at $19.34. According to TipRanks.com, Carr is a

Lexicon Pharmaceuticals (LXRX) Gets a Hold Rating from Needham

Needham analyst Alan Carr maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s shares closed last Monday at $1.72, close to its 52-week low of $1.13. According to TipRanks.com, Carr is a 3-star analyst with

Needham Reiterates Their Hold Rating on Regulus (RGLS)

Needham analyst Alan Carr reiterated a Hold rating on Regulus (RGLS – Research Report) yesterday. The company’s shares closed last Monday at $0.58, close to its 52-week low of $0.50. According to TipRanks.com, Carr is a 3-star analyst with an

Needham Thinks Moderna Inc’s Stock is Going to Recover

In a report issued on August 7, Alan Carr from Needham maintained a Buy rating on Moderna Inc (MRNA – Research Report), with a price target of $28. The company’s shares closed on Friday at $13.33, close to its 52-week